DAMORA THERAPEUTICS, INC. Payments for Repurchase of Initial Public Offering
DAMORA THERAPEUTICS, INC. (DMRA) reported Payments for Repurchase of Initial Public Offering of $21.44 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Cash Flow › Financing Activities
us-gaap:PaymentsForRepurchaseOfInitialPublicOffering · last filed 2026-08-10
- DAMORA THERAPEUTICS, INC. payments for repurchase of initial public offering for fiscal 2020 was $2.11M.
| Period end | Payments for Repurchase of Initial Public Offering 6 month | Payments for Repurchase of Initial Public Offering 12 month |
|---|---|---|
| 2026-06-30 | $21.44M 10-Q · filed 2026-08-10 | |
| 2020-12-31 | $2.11M 10-K · filed 2022-02-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Kardigan, Inc. (KARD) | United States | $1.346B |